RNS Number : 3367D
GSK PLC
15 February 2024
 

GSK plc (the 'Company')

Vesting of Deferred Annual Bonus Plan Deferred Bonus Awards and Sale of Ordinary Shares and American Depositary Shares

This notification sets out the vesting details for Persons Discharging Managerial Responsibilities ('PDMRs') of Deferred Bonus Awards over Ordinary Shares and American Depositary Shares ('ADSs') made in 2021 under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan ('DABP') and subsequent sale of Ordinary Shares and ADSs to meet tax liabilities.  In accordance with the shareholder approved 2017 Remuneration Policy and the DABP rules, the awards comprised a mandatory bonus deferral only. The three-year restricted period for the awards commenced on 10 February 2021 and ended on 12 February 2024.  Dividends accrued on the awards during the restricted period.

The awards were granted in 2021 as restricted awards over ADSs for US participants and as nil-cost options over Ordinary Shares for all other participants.

The closing prices of Ordinary Shares and of ADSs of GlaxoSmithKline plc on 12 February 2024 were £16.264 and $41.07.

 

 

 

 

Transaction notification


1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Emma Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£0.00

.

52,435






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

 

e)

Date of the transaction

2024-02-12

f)

Place of the transaction

 

N/A

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Emma Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£16.5180

.

24,682






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

 

e)

Date of the transaction

2024-02-12

f)

Place of the transaction

 

London Stock Exchange (XLON)


1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Hal Barron

b)

Position/status

Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W2044

b)

Nature of the transaction

The vesting of an award granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



$0.00

.

27,796






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

 

e)

Date of the transaction

2024-02-12

f)

Place of the transaction

 

N/A


 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Hal Barron

b)

Position/status

Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W2044

b)

Nature of the transaction

The sale of ADSs' to meet tax liabilities on the vesting of an award granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



$41.0648

.

14,941






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

 

e)

Date of the transaction

2024-02-12

f)

Place of the transaction

 

New York Stock Exchange (XNYS)


1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Diana Conrad

b)

Position/status

Chief People Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£0.00

.

7,600






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

 

e)

Date of the transaction

2024-02-12

f)

Place of the transaction

 

N/A



1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Diana Conrad

b)

Position/status

Chief People Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£16.5104

.

4,083






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

 

e)

Date of the transaction

2024-02-12

f)

Place of the transaction

 

London Stock Exchange (XLON)



1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

James Ford

b)

Position/status

SVP and Group General Counsel, Legal and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£0.00

9,157






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

                       

e)

Date of the transaction

2024-02-12

f)

Place of the transaction

 

N/A



1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

James Ford

b)

Position/status

SVP and Group General Counsel, Legal and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£16.5056

.

4,319






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

                       

e)

Date of the transaction

2024-02-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sally Jackson

b)

Position/status

SVP, Global Communications and CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£0.00

.

4,627






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

 

e)

Date of the transaction

2024-02-12

f)

Place of the transaction

 

N/A



1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sally Jackson

b)

Position/status

SVP, Global Communications and CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£16.5238

.

2,183






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

 

e)

Date of the transaction

2024-02-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 


1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Luke Miels

b)

Position/status

Chief Commercial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£0.00

.

14,209






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

 

e)

Date of the transaction

2024-02-12

f)

Place of the transaction

 

N/A



1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Luke Miels

b)

Position/status

Chief Commercial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£16.5020

.

166






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

 

e)

Date of the transaction

2024-02-12

f)

Place of the transaction

 

London Stock Exchange (XLON)


 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

David Redfern

b)

Position/status

President Corporate Development

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£0.00

.

11,169






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

 

e)

Date of the transaction

2024-02-12

f)

Place of the transaction

 

N/A



1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

David Redfern

b)

Position/status

President Corporate Development

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£16.5152

.

5,263






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

 

e)

Date of the transaction

2024-02-12

f)

Place of the transaction

 

London Stock Exchange (XLON)



1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Regis Simard

b)

Position/status

President, Global Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£0.00

.

8,414






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

 

e)

Date of the transaction

2024-02-12

f)

Place of the transaction

 

N/A

 



1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Regis Simard

b)

Position/status

President, Global Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£16.4822

3,969






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

 

e)

Date of the transaction

2024-02-12

f)

Place of the transaction

 

London Stock Exchange (XLON)


 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Phil Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£0.00

.

6,532






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

 

e)

Date of the transaction

2024-02-12

f)

Place of the transaction

 

N/A



1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Phil Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£16.4906

.

3,081






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

 

e)

Date of the transaction

2024-02-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Deborah Waterhouse

b)

Position/status

CEO, ViiV Healthcare and President, Global Health, GSK

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£0.00

.

13,426






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

 

e)

Date of the transaction

2024-02-12

f)

Place of the transaction

 

N/A



1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Deborah Waterhouse

b)

Position/status

CEO, ViiV Healthcare and President, Global Health, GSK

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£16.5186

.

6,327






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

 

e)

Date of the transaction

2024-02-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSFSFIIELSEDE
Gsk (LSE:GSK)
過去 株価チャート
から 3 2024 まで 4 2024 Gskのチャートをもっと見るにはこちらをクリック
Gsk (LSE:GSK)
過去 株価チャート
から 4 2023 まで 4 2024 Gskのチャートをもっと見るにはこちらをクリック